Literature DB >> 29802851

Increasing Health Care Burden of Chronic Liver Disease Compared With Other Chronic Diseases, 2004-2013.

Sumeet K Asrani1, Maria Kouznetsova2, Gerald Ogola2, Thomas Taylor3, Andrew Masica2, Brandon Pope2, James Trotter4, Patrick Kamath5, Fasiha Kanwal6.   

Abstract

BACKGROUND & AIMS: Chronic liver disease (CLD) is a common and expensive condition, and studies of CLD-related hospitalizations have underestimated the true burden of disease. We analyzed data from a large, diverse health care system to compare time trends in CLD-related hospitalizations with those in congestive heart failure (CHF) or chronic obstructive pulmonary disease (COPD).
METHODS: We collected data from a large health care system in Texas on hospitalizations related to CLD (n = 27,783), CHF (n = 60,415), and COPD (n = 34,199) from January 1, 2004 through December 31, 2013. We calculated annual hospitalization rates (per 100,000) and compared hospital course, inpatient mortality, ancillary services, and readmissions.
RESULTS: Compared with patients with CHF (median age, 71 years) or COPD (median age, 69 years), patients with CLD were significantly younger (median age, 57 years) (P < .01 vs CHF and COPD). Higher proportions of patients with CLD were uninsured (11.7% vs 5.4% for CHF and 5.4% for COPD, P < .01) and Hispanic (17% for CLD vs 9.3% for CHF and 5.0% for COPD, P < .01). A lower proportion of patients with CLD had Medicare (41.5% vs 68.6% with CHF and 70.1% with COPD, P < .01). From 2004 through 2013, the rate of CLD-related hospitalization increased by 92% (from 1295/100,000 to 2490/100,000), compared with 6.7% for CHF (from 3843/100,000 to 4103/100,000) and 48.8% for COPD (from 1775/100,000 to 2642/100,000). During this time period, CLD-related hospitalizations covered by Medicare increased from 31.8% to 41.5%, whereas hospitalizations covered by Medicare did not change for CHF (remained at 70%) or COPD (remained at 70%). Patients with CLD had longer hospital stays (7.3 days vs 6.2 days for CHF and 5.9 days for COPD, P < .01). A higher proportion of patients with CLD died or were discharged to hospice (14.2% vs 11.5% of patients with CHF and 9.3% of patients with COPD, P < .01), and a smaller proportion had access to postacute care (13.2% vs 23.2% of patients with CHF and 27.4% of patients with COPD, P < .01). A higher proportion of patients with CLD were readmitted to the hospital within 30 days (25% vs 21.9% of patients with CHF and 20.6% with COPD, P < .01).
CONCLUSIONS: Patients with CLD, compared with selected other chronic diseases, had increasing rates of hospitalization, longer hospital stays, more readmissions, and, despite these adverse outcomes, less access to postacute care. Disease management models for CLD are greatly needed to manage the anticipated increase in hospitalizations for CLD.
Copyright © 2018 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cirrhosis; Epidemiology; Temporal; Trend

Mesh:

Year:  2018        PMID: 29802851     DOI: 10.1053/j.gastro.2018.05.032

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  31 in total

Review 1.  Contemporary Epidemiology of Cirrhosis.

Authors:  Jad A Baki; Elliot B Tapper
Journal:  Curr Treat Options Gastroenterol       Date:  2019-06

Review 2.  Magnetic Resonance imaging analysis of liver fibrosis and inflammation: overwhelming gray zones restrict clinical use.

Authors:  D Marti-Aguado; A Rodríguez-Ortega; A Alberich-Bayarri; L Marti-Bonmati
Journal:  Abdom Radiol (NY)       Date:  2020-08-28

3.  Increasing Burden of Hepatic Encephalopathy Among Hospitalized Adults: An Analysis of the 2010-2014 National Inpatient Sample.

Authors:  Grishma Hirode; Eric Vittinghoff; Robert J Wong
Journal:  Dig Dis Sci       Date:  2019-03-13       Impact factor: 3.199

Review 4.  Specific Challenges in Geriatric Cirrhosis and Hepatic Encephalopathy.

Authors:  Jasmohan S Bajaj; Angela Gentili; James B Wade; Michael Godschalk
Journal:  Clin Gastroenterol Hepatol       Date:  2022-08       Impact factor: 13.576

5.  Nationwide analysis of incidence and predictors of 30-day readmissions in patients with decompensated cirrhosis.

Authors:  Mahesh Gajendran; Chandraprakash Umapathy; Abhilash Perisetti; Priyadarshini Loganathan; Alok Dwivedi; Luis A Alvarado; Marc J Zuckerman; Hemant Goyal; Sherif Elhanafi
Journal:  Frontline Gastroenterol       Date:  2021-07-02

6.  Inpatient Frailty Assessment Is Feasible and Predicts Nonhome Discharge and Mortality in Decompensated Cirrhosis.

Authors:  Marina Serper; Sunny Y Tao; Dorothea S Kent; Patrik Garren; Alexander E Burdzy; Jennifer C Lai; Amir Gougol; Pamela M Bloomer; K Rajender Reddy; Michael A Dunn; Andres Duarte-Rojo
Journal:  Liver Transpl       Date:  2021-08-01       Impact factor: 5.799

7.  Incidence and predictors of 30-day hospital readmissions for liver cirrhosis: insights from the United States National Readmissions Database.

Authors:  Sushil Kumar Garg; Hemant Goyal; Itegbemie Obaitan; Pir Ahmad Shah; Shashank Sarvepalli; Loretta Lynn Jophlin; Dupinder Singh; Sumeet Asrani; Patrick S Kamath; Michael D Leise
Journal:  Ann Transl Med       Date:  2021-07

8.  Symptom Burden Is Associated with Increased Emergency Department Utilization among Patients with Cirrhosis.

Authors:  Lisa X Deng; Dorothea S Kent; David L O'Riordan; Steven Z Pantilat; Jennifer C Lai; Kara E Bischoff
Journal:  J Palliat Med       Date:  2021-08-03       Impact factor: 2.947

9.  Cost-Related Nonadherence to Medications Among US Adults With Chronic Liver Diseases.

Authors:  Carlos Lago-Hernandez; Nghia H Nguyen; Rohan Khera; Rohit Loomba; Sumeet K Asrani; Siddharth Singh
Journal:  Mayo Clin Proc       Date:  2021-06-11       Impact factor: 11.104

10.  The Predictive Role of Model for End-Stage Liver Disease-Lactate and Lactate Clearance for In-Hospital Mortality Among a National Cirrhosis Cohort.

Authors:  Nadim Mahmud; Sumeet K Asrani; David E Kaplan; Gerald O Ogola; Tamar H Taddei; Patrick S Kamath; Marina Serper
Journal:  Liver Transpl       Date:  2020-12-09       Impact factor: 5.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.